JP6013346B2 - 即時使用可能なケトロラク製剤 - Google Patents

即時使用可能なケトロラク製剤 Download PDF

Info

Publication number
JP6013346B2
JP6013346B2 JP2013535115A JP2013535115A JP6013346B2 JP 6013346 B2 JP6013346 B2 JP 6013346B2 JP 2013535115 A JP2013535115 A JP 2013535115A JP 2013535115 A JP2013535115 A JP 2013535115A JP 6013346 B2 JP6013346 B2 JP 6013346B2
Authority
JP
Japan
Prior art keywords
ketorolac
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013535115A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013543843A (ja
JP2013543843A5 (enExample
Inventor
ジョセフ パーゴリジー，
ジョセフ パーゴリジー，
アレキサンダー ミロノフ，
アレキサンダー ミロノフ，
チャド， ジェイムズ ピッケンズ，
チャド， ジェイムズ ピッケンズ，
ダグラス， ジャイルズ ジョンソン，
ダグラス， ジャイルズ ジョンソン，
Original Assignee
アールティーユー ファーマシューティカルズ， エルエルシー
アールティーユー ファーマシューティカルズ， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アールティーユー ファーマシューティカルズ， エルエルシー, アールティーユー ファーマシューティカルズ， エルエルシー filed Critical アールティーユー ファーマシューティカルズ， エルエルシー
Publication of JP2013543843A publication Critical patent/JP2013543843A/ja
Publication of JP2013543843A5 publication Critical patent/JP2013543843A5/ja
Application granted granted Critical
Publication of JP6013346B2 publication Critical patent/JP6013346B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2013535115A 2010-10-21 2011-10-21 即時使用可能なケトロラク製剤 Active JP6013346B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40538410P 2010-10-21 2010-10-21
US61/405,384 2010-10-21
US201161481602P 2011-05-02 2011-05-02
US61/481,602 2011-05-02
PCT/US2011/057284 WO2012054831A2 (en) 2010-10-21 2011-10-21 Ready to use ketorolac formulations

Publications (3)

Publication Number Publication Date
JP2013543843A JP2013543843A (ja) 2013-12-09
JP2013543843A5 JP2013543843A5 (enExample) 2015-02-19
JP6013346B2 true JP6013346B2 (ja) 2016-10-25

Family

ID=45973506

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013535115A Active JP6013346B2 (ja) 2010-10-21 2011-10-21 即時使用可能なケトロラク製剤

Country Status (19)

Country Link
US (5) US9421191B2 (enExample)
EP (3) EP4190327A1 (enExample)
JP (1) JP6013346B2 (enExample)
KR (4) KR102307601B1 (enExample)
CN (2) CN108703948A (enExample)
CA (1) CA2814805C (enExample)
CY (1) CY1122516T1 (enExample)
DK (1) DK2616064T3 (enExample)
ES (2) ES2753981T3 (enExample)
HR (1) HRP20191994T1 (enExample)
HU (1) HUE045889T2 (enExample)
LT (1) LT2616064T (enExample)
MX (1) MX346879B (enExample)
PL (1) PL2616064T3 (enExample)
PT (1) PT2616064T (enExample)
RS (1) RS59526B1 (enExample)
SI (1) SI2616064T1 (enExample)
SM (1) SMT201900656T1 (enExample)
WO (1) WO2012054831A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108703948A (zh) 2010-10-21 2018-10-26 Rtu制药有限责任公司 即用型酮咯酸注射液
US10098872B1 (en) 2013-07-22 2018-10-16 William Bradley Worthington Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
US11992484B2 (en) 2013-07-22 2024-05-28 Hutchison Health, Llc Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
US11559521B2 (en) * 2013-07-22 2023-01-24 William Bradley Worthington Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
US11992485B2 (en) 2013-07-22 2024-05-28 Hutchison Health, Llc Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CN103830171B (zh) * 2014-03-04 2015-11-18 鲁南制药集团股份有限公司 一种酮咯酸氨丁三醇注射液及其制备方法
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
KR102465027B1 (ko) * 2015-02-10 2022-11-09 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학 조성물
IT201600075246A1 (it) * 2016-07-19 2018-01-19 Jointherapeutics S R L Composizioni comprendenti una matrice polisaccaridica per il rilascio controllato di principi attivi.
EP4467600A3 (en) * 2017-05-10 2025-03-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
FR3101917B1 (fr) 2019-10-09 2022-07-15 Ifp Energies Now Système de refroidissement à radiateur unique
CN110812325B (zh) * 2019-11-13 2022-04-05 鲁南制药集团股份有限公司 一种提高酮咯酸氨丁三醇注射液存储稳定性的方法
CN119818450A (zh) * 2020-05-19 2025-04-15 南京海融医药科技股份有限公司 一种左酮咯酸的药物组合物及其制备方法
CN114159384B (zh) * 2021-02-07 2023-04-07 南京锐志生物医药有限公司 一种化学性质稳定的低刺激性酮咯酸氨丁三醇注射液
WO2022268190A1 (zh) * 2021-06-24 2022-12-29 上海博志研新药物技术有限公司 一种酮咯酸液体组合物、其制备方法及应用
CN113384524B (zh) * 2021-07-05 2025-08-12 四川尚锐生物医药有限公司 一种稳定的酮咯酸氨丁三醇注射液的制备方法
CN114191384A (zh) * 2021-12-20 2022-03-18 成都倍特药业股份有限公司 一种即用型酮咯酸氨丁三醇和氢溴酸依他佐辛组合液体制剂
CN114432240A (zh) * 2022-03-04 2022-05-06 郑州市中心医院 一种稳定不刺激的酮咯酸氨丁三醇注射液及其制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4089969A (en) 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
US5214052A (en) 1987-07-28 1993-05-25 Mitsubishi Kasei Corporation Method for dissolving arginineamides and pharmaceutical compositions containing them
TWI285644B (en) 1997-07-11 2007-08-21 Toray Industries A stable pharmaceutical composition containing a derivative of 4,5-epoxymorphinan and a water-soluble antioxidant, an oil-soluble antioxidant, a synergist, a sugar and a surfactant
US6608073B1 (en) 1998-10-14 2003-08-19 New Millennium Pharmaceutical Research, Inc. Intranasal codeine for the rapid suppression of cough and rapid relief of pain
US6495535B1 (en) 1999-03-26 2002-12-17 Pozen Inc. High potency dihydroergotamine compositions
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US6509027B2 (en) * 2001-02-12 2003-01-21 Supergen, Inc. Injectable pharmaceutical composition comprising coated particles of camptothecin
US20030191187A1 (en) * 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
EP1615646B2 (en) 2003-04-08 2022-07-27 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
US20070049552A1 (en) 2003-04-14 2007-03-01 Babu Manoj M Fluoroquinolone formulations and methods of making and using the same
US20080317681A1 (en) * 2003-07-11 2008-12-25 Petros Gebreselassie Compositions containing a stain removing complex, and methods of making and using the same
US20050266031A1 (en) 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
AU2005295541B2 (en) * 2004-10-15 2011-02-17 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US8148356B2 (en) 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
BRPI0616127B8 (pt) 2005-09-01 2021-05-25 Baxter Healthcare Sa solução farmacêutica aquosa, estéril, estável, injetável, e seu método de preparação
US20070142478A1 (en) * 2005-12-21 2007-06-21 Erning Xia Combination antimicrobial composition and method of use
EP2001438A2 (en) 2006-02-09 2008-12-17 Macusight, Inc. Stable formulations, and methods of their preparation and use
DOP2007000055A (es) * 2006-04-10 2007-10-31 Senosiain S A De C V Lab Composición farmaceutica que comprende un analgésico y vitaminas
NZ572225A (en) 2006-04-18 2011-05-27 Ekr Therapeutics Inc Pre-mixed pharmaceutical compositions comprising nicardipine, a tonicity agent, and a buffer
US20100010046A1 (en) 2006-06-12 2010-01-14 Ironwood Pharmaceuticals, Inc. Pharmaceutical formulation for parenteral administration
AU2007269835A1 (en) * 2006-06-29 2008-01-10 Schering Corporation Sugar-free storage-stable antihistaminic syrups
US20080014274A1 (en) 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
US20080057023A1 (en) * 2006-08-29 2008-03-06 Chynn Emil W Oxygenated ophthalmic composition
US7589106B2 (en) 2006-09-27 2009-09-15 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
KR100836624B1 (ko) 2006-12-08 2008-06-10 한국전자통신연구원 가변 고속 푸리에 변환 장치 및 그 방법
US20080312154A1 (en) * 2007-06-15 2008-12-18 Barbara Lee Peterlin Administration of adipocytokine and adiponectin for treating headache and methods of diagnosing headache by measuring adiponectin
EP3064198A1 (en) 2007-09-03 2016-09-07 Nanotherapeutics, Inc. Particulate compositions for delivery of poorly soluble drugs
WO2009087658A2 (en) 2007-11-07 2009-07-16 Sun Pharma Advanced Research Company Limited Composition suitable for parenteral administration
US9399012B2 (en) 2007-11-13 2016-07-26 Mallinckrodt Ip Reduced dose intravenous acetaminophen
US20090239836A1 (en) * 2008-03-24 2009-09-24 Mary Lee Ciolkowski Multifunctional Ophthalmic Compositions
US8956636B2 (en) 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprosing ketorolac
US7635773B2 (en) * 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
TWI397038B (zh) * 2008-11-05 2013-05-21 Au Optronics Corp 使用半源極驅動架構之顯示面板及其顯示資料供應方法
JP6188021B2 (ja) * 2010-07-19 2017-08-30 バイオジェン チェサピーク エルエルシー グリブリドおよび他の薬剤の静脈内投与方法
MY173215A (en) 2010-07-21 2020-01-06 Cumberland Pharmaceuticals Inc Acetylcysteine compositions and methods of use thereof
CN108703948A (zh) 2010-10-21 2018-10-26 Rtu制药有限责任公司 即用型酮咯酸注射液

Also Published As

Publication number Publication date
KR102114568B1 (ko) 2020-05-22
EP3632432A1 (en) 2020-04-08
CN103167800A (zh) 2013-06-19
HRP20191994T1 (hr) 2020-02-07
US20220023260A1 (en) 2022-01-27
WO2012054831A3 (en) 2012-06-07
DK2616064T3 (da) 2019-11-11
ES2933198T3 (es) 2023-02-02
MX346879B (es) 2017-04-03
EP2616064A4 (en) 2016-07-20
KR20140012029A (ko) 2014-01-29
KR20200078541A (ko) 2020-07-01
EP3632432B1 (en) 2022-09-14
EP2616064A2 (en) 2013-07-24
US10278959B2 (en) 2019-05-07
US20170007575A1 (en) 2017-01-12
PL2616064T3 (pl) 2020-02-28
KR20180119610A (ko) 2018-11-02
US20190105301A1 (en) 2019-04-11
KR102307601B1 (ko) 2021-09-30
JP2013543843A (ja) 2013-12-09
CN108703948A (zh) 2018-10-26
CA2814805C (en) 2021-11-02
SI2616064T1 (sl) 2019-12-31
CY1122516T1 (el) 2021-01-27
ES2753981T3 (es) 2020-04-15
PT2616064T (pt) 2019-11-06
US20120101142A1 (en) 2012-04-26
US11116750B2 (en) 2021-09-14
RS59526B1 (sr) 2019-12-31
HUE045889T2 (hu) 2020-01-28
EP4190327A1 (en) 2023-06-07
MX2013004393A (es) 2014-09-12
US9421191B2 (en) 2016-08-23
WO2012054831A2 (en) 2012-04-26
EP2616064B1 (en) 2019-08-07
LT2616064T (lt) 2019-11-25
US9962371B2 (en) 2018-05-08
US20180280351A1 (en) 2018-10-04
SMT201900656T1 (it) 2020-01-14
KR20190085561A (ko) 2019-07-18
CA2814805A1 (en) 2012-04-26

Similar Documents

Publication Publication Date Title
JP6013346B2 (ja) 即時使用可能なケトロラク製剤
RU2362560C2 (ru) Фармацевтическая препаративная форма
TWI844703B (zh) 穩定的ast-3424注射液製劑及製備方法
DK2574167T3 (en) LIQUID NOSE SPRAY CONTAINING low-dose naltrexone
TW200817048A (en) Dry powder compound formulations and uses thereof
ES2639859T3 (es) Inhibidor de la tolerancia analgésica
US20220387421A1 (en) Drug products for intranasal administration and uses thereof
HK40026993B (en) Ready to use ketorolac formulations
HK40026993A (en) Ready to use ketorolac formulations
WO2014083071A1 (en) Injectable liquid formulation of the combination of tramadol and paracetamol
HK1262803A1 (en) Ready to use ketorolac formulations
TWI905111B (zh) 含有對硼苯基丙胺酸之注射液劑
WO2007022609A1 (en) Pharmaceutical composition of morphine in ready-to-use injectable solution form and single dosage form of morphine for epidural or intrathecal administration
US11446311B2 (en) Methods for treating pain associated with sickle cell disease
GB2634647A (en) An oral liquid formulation of methocarbamol
WO2007069070A2 (en) Aseptically filled multidose injectable dosage forms of granisetron
CN1868475A (zh) 氢溴酸东莨菪碱鼻腔喷雾剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141222

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160329

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160726

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160824

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160921

R150 Certificate of patent or registration of utility model

Ref document number: 6013346

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250